GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $87.4286.

A number of research firms recently issued reports on WGS. Canaccord Genuity Group set a $75.00 target price on GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research cut GeneDx from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Craig Hallum restated a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st.

Insider Activity

In other GeneDx news, CFO Kevin Feeley sold 3,729 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares of the company’s stock, valued at $2,428,004.58. This represents a 8.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister acquired 46,273 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the acquisition, the director directly owned 4,784,570 shares of the company’s stock, valued at approximately $186,167,618.70. The trade was a 0.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have acquired 2,256,420 shares of company stock valued at $93,144,340 and have sold 21,699 shares valued at $1,295,646. 25.17% of the stock is currently owned by corporate insiders.

Institutional Trading of GeneDx

Hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its position in shares of GeneDx by 2.1% in the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after acquiring an additional 113 shares during the last quarter. Cerity Partners LLC grew its stake in shares of GeneDx by 6.0% during the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after buying an additional 142 shares during the period. Main Management ETF Advisors LLC increased its holdings in shares of GeneDx by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after buying an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of GeneDx by 5.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after buying an additional 181 shares during the last quarter. Finally, Strs Ohio raised its position in shares of GeneDx by 8.7% in the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after buying an additional 200 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Multiple law firms are urging investors to join or lead a securities fraud class action against GeneDx over alleged misstatements related to the Fabric Genomics acquisition. Article
• Neutral Sentiment: The lawsuits focus on a class period from April 16, 2025 through May 4, 2026, with the lead plaintiff deadline approaching on August 3, 2026. Article
• Negative Sentiment: The new legal overhang adds uncertainty for GeneDx after prior allegations tied to a sharp share-price decline and a disappointing earnings report. Article

GeneDx Price Performance

GeneDx stock opened at $65.42 on Friday. The firm has a market capitalization of $1.94 billion, a PE ratio of -24.41 and a beta of 1.90. GeneDx has a 52 week low of $32.21 and a 52 week high of $170.87. The firm’s 50-day simple moving average is $54.36 and its 200 day simple moving average is $78.47. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the previous year, the firm posted ($0.23) EPS. On average, equities research analysts predict that GeneDx will post -1 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.